Innvolution Expands Global Presence with New Subsidiary in Singapore

Innvolution Healthcare Private Limited

Bengaluru (Karnataka) [India], December 13: Innvolution, a leading innovator in cardiovascular solutions, proudly announces the establishment of its first international subsidiary in Singapore, marking a significant milestone in the company’s growth strategy. This strategic move is poised to be a game-changer for Innvolution’s Cath Lab division, providing a platform to expand its footprint in Southeast Asian countries.

The decision to open a subsidiary in Singapore aligns with Innvolution’s commitment to advancing cardiac care globally. With a focus on delivering world-class solutions, Innvolution aims to bridge the gap in cardiovascular services and extend its impact beyond borders. The Singapore subsidiary will serve as a regional hub, facilitating enhanced accessibility to cutting-edge cardiac care technologies in the Southeast Asian market.

Innvolution has garnered notable success in India, particularly for its Award-winning Cath Labs and Drug Eluting Stents. The company’s dedication to excellence and innovation has resulted in a strong presence in the Indian market, solidifying its reputation as a leader in the field. The expansion to Singapore is a testament to Innvolution’s vision of becoming a global force in cardiac care.

“We are excited about the opening of our Singapore subsidiary, which represents a pivotal step in our international expansion strategy,” said Mr. Gaurav Agarwal, Managing Director at Innvolution. “This move not only strengthens our presence in Southeast Asia but also underscores our unwavering commitment to advancing cardiac care on a global scale. We look forward to contributing significantly to the cardiovascular health landscape in the region.”

Innvolution remains dedicated to its mission of creating differentiated solutions in medical imaging and making cardiac care more effective and accessible worldwide. The establishment of the Singapore subsidiary is a reflection of Innvolution’s pursuit of excellence and its commitment to revolutionizing cardiac care across borders.

Mr. Vikram Singh, with 25 years of experience in operating and managing businesses in ASEAN/Asia, will serve as the Director/COO overseeing our Singapore subsidiary.

For media inquiries, please contact:

Praveen Daga

Head of Marketing

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

Business

Kingston Technology Powers Innvolution Healthcare with Reliable Memory and Storage Solutions

Behind every dependable medical system is a foundation of consistent memory, reliable storage, and trusted engineering support. New Delhi [India], August 25: India’s healthcare technology landscape is undergoing a quiet but profound transformation. As hospitals, diagnostic centers, and medical device innovators increasingly rely on digital intelligence, the systems that support patient care are becoming more […]

Read More
Business

Best Crypto Presale in 2026: AlphaPepe Utility Narrative Solidifies Its Lead Over Pepeto and Apeing

The best crypto presale in 2026 race is getting more competitive, but retail buyers are increasingly looking beyond branding and promises. The projects standing out now are the ones showing what they can actually deliver before their tokens reach exchanges, and that is where AlphaPepe is beginning to separate itself from names such as Pepeto […]

Read More
Business

LANXESS increases sales and earnings in the second quarter of 2026

Sales of EUR 1.561 billion, up 6.5 percent from the same quarter last year Mumbai (Maharashtra) [India], August 25: The specialty chemicals company LANXESS improved sales and earnings in the second quarter of 2026 compared with the prior year—despite a continued weak economic environment and ongoing geopolitical uncertainties. The Group generated sales of EUR 1.561 billion, […]

Read More